Close

Raymond James Downgrades Dipexium Pharmaceuticals (DPRX) to Market Perform

Go back to Raymond James Downgrades Dipexium Pharmaceuticals (DPRX) to Market Perform

Dipexium Pharma (DPRX) will resume trading at 7:30am ET

October 25, 2016 7:11 AM EDT

Dipexium Pharma (Nasdaq: DPRX) will resume trading at 7:30am EDT.

... More

Dipexium Pharma (DPRX) Announces Locilex Phase 3s Missed Primary Endpoints

October 25, 2016 7:04 AM EDT

Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) announced that the OneStep-1 and OneStep-2 Phase 3 clinical trials of Locilex (pexiganan cream 0.8%) in patients with mild infections of diabetic foot ulcers (Mild DFI) did not meet the primary clinical endpoint of superiority versus vehicle plus standardized wound care and also did not show any meaningful difference in wound closure rate between the Locilex arm and the vehicle arm in each study. Neither trial met the secondary endpoint of demonstrating a higher rate of eradication of bacteria for the Locilex arm. While the overall adverse event incidence was comparable... More

Dipexium Pharma (DPRX) trading halted with news pending

October 25, 2016 6:56 AM EDT

Dipexium Pharma (NASDAQ: DPRX) trading halted with news pending.

... More